Fulgent Genetics, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $90.4 million (+7.5% year over year). It usually reports 30–58 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 26, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Friday. Based on last year's release for the same quarter on Feb 27, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 30–58 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
90
+7.5%
|
-13
-99.0%
|
—
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
85
+4.4%
|
-30
-55.8%
|
—
|
|
May 1, 2026
31 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
71
-3.2%
|
-25
-115.3%
|
—
|
|
Feb 27, 2026
58 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
83
+9.3%
|
-23
-297.7%
|
—
|
|
Nov 7, 2025
38 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
84
+17.2%
|
-7
+54.9%
|
—
|
|
Aug 1, 2025
32 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
82
+15.2%
|
-19
-117.6%
|
—
|
|
May 2, 2025
32 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
73
+13.9%
|
-12
+14.4%
|
—
|
|
Feb 28, 2025
59 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
76
+8.1%
|
-6
+95.4%
|
—
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- FLGT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- El Monte, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1674930
- Former names
- Fulgent Diagnostics, Inc. (until Jul 15, 2016)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.